Skip to main content
S&P 5007,773.95+0.66%DOW51,267.90+0.18%NASDAQ27,477.31+1.05%BTC$85,823.00-0.87%ETH$2,714.23-0.50%GOLD$4,166.20+0.23%OIL$89.41-0.02%
Smart Investors Daily
SID Premium
PL

NASDAQ · PLRX

Pliant Therapeutics, Inc.

Healthcare · Biotechnology

$1.03

Down-$0.01 (-0.48%)

Updated Oct 6, 2026, 8:53 AM

SID Score

2.9/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
80.8M
P/E ratio
-0.46
Dividend yield
0.00%
52-week range
$1.02 – $1.95
Volume
295.62K
Avg. volume
1.08M

Price performance · PLRX

PLRX price history

1M range · 20 trading sessions · Daily adjusted prices

Prices through Oct 5, 2026

PLRX closed at $1.03 after 20 trading sessions, down 9.25% for the selected period.

Last close
$1.03
Period change
-9.25%
Period low
$1.03
Period high
$1.17
Daily close
View OHLC price history
PLRX OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 5, 2026$1.04$1.054$1.02$1.03295.62K
Oct 2, 2026$1.06$1.065$1.03$1.035402.81K
Oct 1, 2026$1.10$1.10$1.05$1.05379.55K
Sep 30, 2026$1.09$1.09$1.07$1.08238.68K
Sep 29, 2026$1.09$1.12$1.08$1.08214.5K
Sep 28, 2026$1.08$1.10$1.0709$1.08349.13K
Sep 25, 2026$1.14$1.14$1.08$1.08450.19K
Sep 24, 2026$1.13$1.15$1.11$1.14398.03K
Sep 23, 2026$1.14$1.14$1.10$1.125254.28K
Sep 22, 2026$1.12$1.15$1.11$1.14326.68K
Sep 21, 2026$1.12$1.13$1.11$1.11149.29K
Sep 18, 2026$1.13$1.13$1.09$1.11438.69K
Sep 17, 2026$1.09$1.14$1.09$1.13308.09K
Sep 16, 2026$1.12$1.17$1.07$1.07983.07K
Sep 15, 2026$1.15$1.155$1.11$1.12502.03K
Sep 14, 2026$1.16$1.18$1.15$1.15208.88K
Sep 11, 2026$1.14$1.18$1.14$1.17173.46K
Sep 10, 2026$1.13$1.16$1.13$1.13299.4K
Sep 9, 2026$1.12$1.17$1.12$1.15450.17K
Sep 8, 2026$1.11$1.175$1.11$1.135682.89K

Latest PLRX news

The latest Smart Investors Daily articles mentioning PLRX.

Stock researchCompany · Overview

PLRX research

Overview

Company profile and research snapshot.

Company profile

Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis and related diseases. Its primary product candidate is bexotegrast (PLN-74809), an oral, small molecule, that the company is developing for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$31.14
Implied upside
—
Analysts
—
PLRX recent ratings
DateFirmRatingTarget
Mar 13, 2026Canaccord GenuityHold—
Mar 12, 2026Piper SandlerOverweight—
Nov 7, 2025RBC CapitalSector Perform—
Oct 10, 2025JP MorganUnderweight—
Aug 8, 2025Piper SandlerOverweight—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 30, 2026

Pliant Therapeutics Appoints David Raben, M.D., as Chief Medical Officer

Leader in targeted immuno-oncology drug development brings three decades of academic and biopharmaceutical oncology expertise SOUTH SAN FRANCISCO, Calif., Sept. 30, 2026 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical-stage biotechnology company focused on the discovery and development of integrin-based therapeutics, today announced the appointment of David Raben, M.D., as Chief Medical Officer. Dr. Raben brings more than 30 years of experience in academic translational

Benzinga · Aug 11, 2026

Pliant Therapeutics Q2 EPS $(0.36) Misses $(0.34) Estimate

Pliant Therapeutics (NASDAQ:PLRX) reported quarterly losses of $(0.36) per share which missed the analyst consensus estimate of $(0.34) by 5.88 percent. This is a 49.3 percent increase over losses of $(0.71) per share

Yahoo · Jul 13, 2026

Pliant Therapeutics Names Flavia Borellini, Ph.D. and Robert Iannone, M.D., M.S.C.E. to Board of Directors

Appointments bring global oncology drug development experience and deepen Board’s operational and regulatory expertise SOUTH SAN FRANCISCO, Calif., July 13, 2026 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical-stage biotechnology company focused on the discovery and development of integrin-based therapeutics, today announced the appointments of Flavia Borellini, Ph.D. and Robert Iannone, M.D., M.S.C.E. to its Board of Directors. "On behalf of the Board of Directors, I am

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By